Literature DB >> 29085

Selective defect of precursor T cells associated with apparently normal B lymphocytes in severe combined immunodeficiency disease.

C Griscelli, A Durandy, J L Virelizier, J J Ballet, F Daguillard.   

Abstract

Two patients, one with an autosomal and the other a sex-linked form of severe combined immunodeficiency, had more than 95% B cells in their peripheral blood. Despite an increased absolute number of B lymphocytes, the patients were unable to produce serum antibodies. In each patient, geno- or pheno-identical bone marrow transplantation was followed by the visualization of a thymus shadow and the appearance of both cellular and humoral functions. Chromosome of allotype studies showed that the T cell originated from the donor whereas serum immunoglobulins were synthesized by host B cells. In these patients the pathogenesis appears to be a selective defect of bone marrow precursor T cells without concomitant intrinsic B cell defect. The successful outcome of the graft in these two patients, who are now, respectively, 5 years and 11 months of age and free of infections, indicates that the preferred form of therapy in such patients is transplantation of bone marrow stem cells, which populate the thymus and mature slowly into T cells that cooperate fully with host B cells in synthesis of antibody.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 29085     DOI: 10.1016/s0022-3476(78)81146-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  13 in total

1.  Close linkage of the locus for X chromosome-linked severe combined immunodeficiency to polymorphic DNA markers in Xq11-q13.

Authors:  G de Saint Basile; B Arveiler; I Oberlé; S Malcolm; R J Levinsky; Y L Lau; M Hofker; M Debre; A Fischer; C Griscelli
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

2.  Nonrandom X chromosome inactivation in B cells from carriers of X chromosome-linked severe combined immunodeficiency.

Authors:  M E Conley; A Lavoie; C Briggs; P Brown; C Guerra; J M Puck
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

3.  Increased radiosensitivity of granulocyte macrophage colony-forming units and skin fibroblasts in human autosomal recessive severe combined immunodeficiency.

Authors:  M Cavazzana-Calvo; F Le Deist; G De Saint Basile; D Papadopoulo; J P De Villartay; A Fischer
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

4.  Growth hormone deficiency and combined immunodeficiency.

Authors:  M L Tang; A S Kemp
Journal:  Arch Dis Child       Date:  1993-02       Impact factor: 3.791

5.  Lymphocyte subpopulations in primary immunodeficiency disorders.

Authors:  S Gupta
Journal:  Indian J Pediatr       Date:  1982 May-Jun       Impact factor: 1.967

6.  Immunoreconstitution by peripheral blood leukocytes in adenosine deaminase-deficient severe combined immunodeficiency.

Authors:  K C Rich; C M Richman; E Mejias; P Daddona
Journal:  J Clin Invest       Date:  1980-08       Impact factor: 14.808

7.  X-linked severe combined immunodeficiency. Diagnosis in males with sporadic severe combined immunodeficiency and clarification of clinical findings.

Authors:  M E Conley; R H Buckley; R Hong; C Guerra-Hanson; C M Roifman; J A Brochstein; S Pahwa; J M Puck
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

8.  Heterogeneity of b lymphocyte differentiation in severe combined immunodeficiency disease.

Authors:  S G Pahwa; R N Pahwa; R A Good
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

9.  Evidence that X-linked severe combined immunodeficiency is not a differentiation defect of T lymphocytes.

Authors:  J Goodship; S Malcolm; R J Levinsky
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

10.  Genetic study of a new X-linked recessive immunodeficiency syndrome.

Authors:  G de Saint-Basile; F Le Deist; M Caniglia; Y Lebranchu; C Griscelli; A Fischer
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.